Phase III data from a large clinical trial confirmed that remibrutinib led to complete resolution of chronic inducible urticaria in most patients treated.
Tag: Phase
Survodutide Phase 3 Trials Show Weight Loss Drug May Have Significant Clinical Benefit
Two phase 3 trials of Boehringer Ingelheim’s investigational weight loss drug Survodutide suggest it may offer substantial metabolic benefits.